FFAR4 Genotype

Your body has a built-in sensor that reads the fat you eat and uses that information to tune inflammation, insulin response, and appetite. The gene behind that sensor is FFAR4 (free fatty acid receptor 4), also called GPR120. A single inherited change in this gene may shift how your body handles dietary fat for the rest of your life.

This test looks at your FFAR4 genotype: the specific version of the gene you were born with. It is most useful if you have a family history of obesity or type 2 diabetes, or if your weight and blood sugar do not respond to diet the way you would expect. Clinical guidelines do not currently recommend FFAR4 genotyping for routine metabolic risk stratification, so the result is best used as one input among many.

What FFAR4 Does in Your Body

FFAR4 is a receptor that sits on the surface of cells in your gut, fat tissue, and immune cells. When long-chain fatty acids from your food, including omega-3 fats, reach these cells, FFAR4 turns on signals that calm inflammation, improve how cells respond to insulin, and influence how full you feel after eating.

A working version of this gene helps your body translate dietary fat into a more favorable metabolic state. A weaker version may blunt those signals, which is one reason inherited differences in FFAR4 keep being studied for their links to weight and blood sugar.

Obesity Risk

A study in 38 children with obesity found that those with the lowest FFAR4 gene activity were more likely to have extreme obesity. Carriers of the T minor allele of the rs11187533 variant had higher FFAR4 activity than those with two copies of the C allele, and lower activity was linked to the C allele specifically.

A 2012 study in European adults reported that a loss-of-function change called p.R270H in FFAR4 was tied to greater obesity risk. The picture is not settled, though: a later Danish study of 11,479 people and a European consortium meta-analysis of up to about 71,000 participants did not find an association between p.R270H and obesity. The animal work behind the original finding suggests the receptor helps prevent fat accumulation, but the human evidence for an obesity link is mixed.

Type 2 Diabetes Risk

In a French study that genotyped p.R270H across roughly 18,000 adults, the variant was associated with slightly higher fasting blood sugar (about 0.09 mmol/L) in the 8,996 non-diabetic participants. It did not, on its own, raise the overall odds of developing type 2 diabetes in that cohort, and the same Danish replication study did not confirm the fasting glucose association either.

The picture shifted once diet was added to the analysis. In the D.E.S.I.R. study of 5,212 French adults, carriers of the p.R270H variant who ate a low-fat diet had a higher risk of developing type 2 diabetes over time than non-carriers eating the same way. No excess risk was seen for variant carriers in the higher dietary fat groups. The variant does not act in isolation, but the gene-diet interaction is more complex than a simple "more fat equals more risk" story.

Insulin Resistance

In the same group of children studied for obesity, those with the lowest FFAR4 gene activity had higher fasting insulin and worse scores on standard insulin resistance measures, including HOMA-IR (a calculation that estimates how hard your body has to work to keep blood sugar in range). They also scored lower on QUICKI, a related measure of insulin sensitivity.

Because lower FFAR4 activity tracked with the C allele of rs11187533, this variant may be one inherited reason some children drift toward insulin resistance. In adults, however, the p.R270H variant was not associated with fasting insulin or HOMA-IR, so the inherited contribution to insulin resistance is not consistent across studies.

Reading a Counterintuitive Pattern

FFAR4 is not a simple high-equals-bad number. It is a genotype that may shape how your body responds to fat in your diet. The p.R270H variant has been linked to slightly higher fasting glucose in one large French study but not in a large Danish replication, and it did not by itself increase diabetes diagnoses. In the D.E.S.I.R. cohort, the excess diabetes risk for carriers showed up specifically among low-fat eaters, not among higher-fat eaters, a counterintuitive pattern that has not yet been confirmed in other cohorts. Think of the gene as one possible input into your metabolic picture, not your destiny.

Your One-Time Result

Your FFAR4 genotype is fixed at birth and does not change. You do not need to retest the gene itself. The value comes from acting on the result over years.

What does need ongoing tracking are the metabolic markers the gene may influence. Whether or not you carry an FFAR4 variant, general metabolic monitoring with fasting glucose, HbA1c (a measure of average blood sugar over about three months), and a fasting insulin or HOMA-IR calculation is reasonable, especially if you have a family history of diabetes or obesity. Body composition and waist measurements also belong in that loop. FFAR4 effect sizes in published studies are small, so the genotype alone should not dictate aggressive intervention.

When Results Can Be Misleading

• Variant panel coverage: this test reads specific known FFAR4 variants. A result that does not flag a risk variant does not rule out other rare changes elsewhere in the gene that the assay was not designed to detect.
• Ancestry-specific frequencies: the best-studied FFAR4 variants come largely from European populations, and even within Europe the obesity and fasting glucose findings did not replicate consistently. If your ancestry is different, the published risk estimates may not apply to you in the same way.
• Variants of uncertain significance: the lab may occasionally report a change in FFAR4 whose clinical meaning is not yet established. This is not the same as a known risk variant, and it should not be treated as one.
• Confusion with consumer ancestry reports: clinical-grade genotyping is more reliable than a 23andMe-style raw data file for medical decisions. If your only prior information came from a consumer report, a clinical assay is worth doing before acting on the result.

What to Do With an Out-of-Pattern Result

If your genotype shows a higher-risk FFAR4 variant, the response is not to repeat the gene test. The reported effect sizes are small and no clinical guideline currently uses FFAR4 to guide treatment, so the practical step is to keep an eye on the metabolic markers the gene may touch.

That means tracking fasting glucose, HbA1c, fasting insulin or HOMA-IR, a standard lipid panel, and waist or body composition over time. If multiple metabolic markers begin to drift, an endocrinologist or a longevity-focused physician can help you act earlier than guidelines aimed at the general population would suggest. Your first-degree relatives (parents, siblings, children) share half your genes on average and may benefit from testing too, especially if there is a family history of obesity, prediabetes, or type 2 diabetes.